Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780305 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07780305 · ClinicalTrials.gov record · last posted 2026-08-26

ABCSG R07 Rectal Cancer Registry

Study acronym: ABCSG R07 RCR
StatusNot Yet Recruiting
PhaseNot specified
Started2026-09-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair capacity). However, treatment can vary considerably between hospitals in Austria. These differences may include the type and duration of treatment, as well as the active ingredients used. There are currently no clear recommendations on which exact treatment is best for each specific case. The aim of this observational study is to collect information on the different treatments used in Austria for patients with localized rectal cancer and to document the outcomes of these treatments. Only information and samples collected as part of the patients' routine care will be used for the study. Participation in the study will not change or affect the treatment chosen by the treating physician.
Trial Details
NCT Number NCT07780305
Lead Sponsor Austrian Breast & Colorectal Cancer Study Group
Collaborators: GlaxoSmithKline
Conditions Rectal Cancer, Adenocarcinoma of Rectum
Enrollment 600 participants
Start Date 2026-09-01
Primary Completion 2033-02-01 (estimated)
Study Completion 2033-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-26